Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.57 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642715 | 0.84 | CNR1 (0.61) | CNR1CNR2KDM4C | |
| SCHEMBL3581287 | 0.83 | CNR1 (0.66) | CNR1HRH2CNR2ICMT | |
| SCHEMBL2654788 | 0.83 | CNR2 (0.51) | CNR1CNR2 | |
| SCHEMBL12486009 | 0.80 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL7291968 | 0.80 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL2644061 | 0.79 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL2642626 | 0.79 | CNR1 (0.61) | CNR1CNR2KDM4C | |
| SCHEMBL2654320 | 0.79 | HTR3A (0.47) | CNR1CNR2KDM4C | |
| SCHEMBL2642840 | 0.78 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL30568908 | 0.77 | CNR1 (0.43) | CNR1HRH2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
| EP-1532980-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | CNR1 616/4885HRH2 736/4885CNR2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.